Breathe
again
Presenting BES-1001
Effective drug-free and non-invasive treatment of nasal congestion and pain
with a handheld, connected medical device
Coming Soon!
1 in 5 people
in the world suffer from chronic nasal congestion
Constant discomfort, pain and difficulty sleeping significantly affect patients’ quality of life
Side effects, limited efficacy and inconvenience are key limitations of available treatments
As a result of suboptimal treatments available, the societal burden of chronic nasal congestion can exceed $10.000 /patient /year
Orlandi et al., International Consensus Statement on Allergy and Rhinology: Rhinosinusitis Executive Summary (2016)
Wise et al., International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2020)
BES-1001
is a medical device that treats nasal congestion and facial pain using Precisely Modulated Acoustic Energy (PMAE)
- Drug-free Device can be used as a monotherapy or in combination with medications
- Non-invasive Treatment is comfortable and convenient, lasting 1 minute/side of the face
- Handheld Easy-to-use, pocket-sized and connected, BES-1001 can be used anywhere
BES-1001
is a medical device that treats nasal congestion and facial pain using Precisely Modulated Acoustic Energy (PMAE)
- Drug-free Device can be used as a monotherapy or in combination with medications
- Non-invasive Easy-to-use, pocket-sized and connected, BES-1001 can be used anywhere
- Handheld Easy-to-use, pocket-sized and connected, BES-1001 can be used anywhere
Human studies
showed BES-1001’s patent- protected frequency range
promotes clearance of nasal congestion
- Proof-of-concept resonance validation study; 2. Cold air challenge; 3. Saccharine test.
Patients eligible
for treatment include populations with highly prevalent ENT disorders
CRS: Chronic rhinosinusitis;
Figures refer to EU4, UK, US and Japan;
Differentiated
from devices approved to treat nasal congestion or facial pain
Device ready
for clinical development and IP protected
Tech platform
based on acoustic wave therapy and IP presents major upsides
*Figures refer to EU4, UK, US and Japan
Networked
and lean operating model combining internal experience in the life sciences with external experience of international service providers
Konstantinos Efthymiopoulos
PharmD, PhD, MBA
Chairman & Managing Director
Current key partners
